Diffuse Large B-Cell Lymphoma research hub
5 indexed studies · 0 currently recruiting
- active not recruitingPHASE1
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
This study is looking into a new tablet medicine, ABBV-525, for adults with certain B-cell cancers like lymphoma and leukaemia. It aims to check its safety, how well the body handles it, and if it could help treat these conditions.
United States · Australia · Belgium - authorisedHuman Pharmacology (Phase I)- First administration to humans
Phase Ia/Ib Study of UBX-303061 in Subjects with Relapsed/Refractory B-Cell Malignancies
This early-stage research study is looking into a new medicine, UBX-303061, for people in the UK who have certain types of blood cancers called B-cell malignancies. It's the first time this medicine is being given to people, to check its safety and how it works.
Poland - ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
This study looks at a new drug, mosunetuzumab, by itself and with another drug, atezolizumab. It's for people with certain types of lymphoma or leukaemia that haven't responded to other treatments. The main goals are to check if the new drug is safe, how well it works, and how the body handles it.
Spain · Germany - active not recruitingPHASE3
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
This study looks at the long-term safety of a drug called zanubrutinib for people with certain blood cancers (B-cell malignancies). It's for those who have already taken zanubrutinib in a previous study.
United States · Australia · China - active not recruitingPHASE2
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
This study offers ongoing treatment for people with certain blood cancers (B-cell malignancies) who are already taking part in a different study with a drug called parsaclisib. It lets them continue their treatment if it's helping them.
United States · Austria · Belgium